药物洗脱支架经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干冠状动脉疾病的个体患者数据荟萃分析
该个体患者数据荟萃分析纳入4项随机对照试验共4394例左主干冠状动脉疾病患者,比较药物洗脱支架经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术(CABG)的长期结局。5年全因死亡在PCI组为11.2%、CABG组为10.2%(HR 1.10,95%CI 0.91-1.32;p=0.33),差异无统计学意义;贝叶斯分析提示PCI死亡风险高于CABG的概率为85.7%,但差异更可能小于1.0%(每年<0.2%)。PCI组自发性心肌梗死和再次血运重建风险更高,卒中风险总体无差异但第一年PCI更低。
要点
- 左主干病变患者PCI与CABG的5年全因死亡无统计学显著差异(HR 1.10,95%CI 0.91-1.32)。
- PCI组自发性心肌梗死(HR 2.35)和再次血运重建(HR 1.78)风险显著高于CABG组。
- 卒中风险总体无差异(HR 0.84),但随机化后第一年PCI组卒中风险更低(HR 0.37)。
核心结论
- 在左主干冠状动脉疾病且冠状动脉解剖复杂度多为低或中等的患者中,PCI与CABG的5年全因死亡无统计学显著差异,但贝叶斯方法提示差异很可能存在(更可能每年<0.2%),倾向于CABG。
- 两种策略在心肌梗死、卒中和血运重建风险方面存在权衡。
- 作者认为,心脏团队方法沟通预期结局差异可能有助于患者做出治疗决策。
研究设计与样本
- 个体患者数据荟萃分析,检索MEDLINE、Embase和Cochrane数据库,检索词为「left main」、「percutaneous coronary intervention」或「stent」以及「coronary artery bypass graft*」,纳入数据库建库至2021年8月31日发表的英文随机对照试验(RCT),要求比较PCI(药物洗脱支架)与CABG且所有患者随访至少5年全因死亡率。
- 共纳入4项RCT(SYNTAX、PRECOMBAT、NOBLE和EXCEL),4394例患者随机分配至PCI(n=2197)或CABG(n=2197),中位SYNTAX评分为25.0(IQR 18.0-31.0)。
- 采用一步法,事件率用Kaplan-Meier法计算,治疗组比较用Cox frailty模型,以试验为随机效应;贝叶斯分析计算PCI与CABG主要终点绝对风险差异大于0.0%、至少1.0%、2.5%或5.0%的概率。
主要发现
- 5年全因死亡的Kaplan-Meier估计:PCI组11.2%(95%CI 9.9-12.6) vs CABG组10.2%(95%CI 9.0-11.6),HR 1.10(95%CI 0.91-1.32;p=0.33),绝对风险差异0.9%(95%CI -0.9至2.8),无统计学意义。
- 贝叶斯分析:5年死亡PCI高于CABG的概率为85.7%;该差异更可能小于1.0%(每年<0.2%)。
- 自发性心肌梗死:PCI组6.2%(95%CI 5.2-7.3) vs CABG组2.6%(95%CI 2.0-3.4),HR 2.35(95%CI 1.71-3.23;p<0.0001)。
- 再次血运重建:PCI组18.3%(95%CI 16.7-20.0) vs CABG组10.7%(95%CI 9.4-12.1),HR 1.78(95%CI 1.51-2.10;p<0.0001)。
- 卒中总体风险:PCI组2.7%(95%CI 2.0-3.5) vs CABG组3.1%(95%CI 2.4-3.9),HR 0.84(95%CI 0.59-1.21;p=0.36),无显著差异;但随机化后第一年PCI组卒中风险更低(HR 0.37,95%CI 0.19-0.69)。
关键数值与推荐
- 主要终点为5年全因死亡率;次要终点为心血管死亡、自发性心肌梗死、围手术期心肌梗死、卒中和再次血运重建。
- 纳入标准:比较PCI(药物洗脱支架)与CABG的RCT,左主干冠状动脉疾病,所有患者随访至少5年全因死亡率,英文发表,数据库建库至2021年8月31日。
- 中位SYNTAX评分25.0(IQR 18.0-31.0)。
临床怎么用
- 作者认为,心脏团队方法沟通预期结局差异可能有助于患者做出治疗决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal revascularisation strategy for patients with left main coronary artery disease is uncertain. We therefore aimed to evaluate long-term outcomes for patients treated with percutaneous coronary intervention (PCI) with drug-eluting stents versus coronary artery bypass grafting (CABG). METHODS: In this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane database using the search terms "left main", "percutaneous coronary intervention" or "stent", and "coronary artery bypass graft*" to identify randomised controlled trials (RCTs) published in English between database inception and Aug 31, 2021, comparing PCI with drug-eluting stents with CABG in patients with left main coronary artery disease that had at least 5 years of patient follow-up for all-cause mortality. Two authors (MSS and BAB) identified studies meeting the criteria. The primary endpoint was 5-year all-cause mortality. Secondary endpoints were cardiovascular death, spontaneous myocardial infarction, procedural myocardial infarction, stroke, and repeat revascularisation. We used a one-stage approach; event rates were calculated by use of the Kaplan-Meier method and treatment group comparisons were made by use of a Cox frailty model, with trial as a random effect. In Bayesian analyses, the probabilities of absolute risk differences in the primary endpoint between PCI and CABG being more than 0·0%, and at least 1·0%, 2·5%, or 5·0%, were calculated. FINDINGS: Our literature search yielded 1599 results, of which four RCTs-SYNTAX, PRECOMBAT, NOBLE, and EXCEL-meeting our inclusion criteria were included in our meta-analysis. 4394 patients, with a median SYNTAX score of 25·0 (IQR 18·0-31·0), were randomly assigned to PCI (n=2197) or CABG (n=2197). The Kaplan-Meier estimate of 5-year all-cause death was 11·2% (95% CI 9·9-12·6) with PCI and 10·2% (9·0-11·6) with CABG (hazard ratio 1·10, 95% CI 0·91-1·32; p=0·33), resulting in a non-statistically significant absolute risk difference of 0·9% (95% CI -0·9 to 2·8). In Bayesian analyses, there was an 85·7% probability that death at 5 years was greater with PCI than with CABG; this difference was more likely than not less than 1·0% (<0·2% per year). The numerical difference in mortality was comprised more of non-cardiovascular than cardiovascular death. Spontaneous myocardial infarction (6·2%, 95% CI 5·2-7·3 vs 2·6%, 2·0-3·4; hazard ratio [HR] 2·35, 95% CI 1·71-3·23; p<0·0001) and repeat revascularisation (18·3%, 16·7-20·0 vs 10·7%, 9·4-12·1; HR 1·78, 1·51-2·10; p<0·0001) were more common with PCI than with CABG. Differences in procedural myocardial infarction between strategies depended on the definition used. Overall, there was no difference in the risk of stroke between PCI (2·7%, 2·0-3·5) and CABG (3·1%, 2·4-3·9; HR 0·84, 0·59-1·21; p=0·36), but the risk was lower with PCI in the first year after randomisation (HR 0·37, 0·19-0·69). INTERPRETATION: Among patients with left main coronary artery disease and, largely, low or intermediate coronary anatomical complexity, there was no statistically significant difference in 5-year all-cause death between PCI and CABG, although a Bayesian approach suggested a difference probably exists (more likely than not <0·2% per year) favouring CABG. There were trade-offs in terms of the risk of myocardial infarction, stroke, and revascularisation. A heart team approach to communicate expected outcome differences might be useful to assist patients in reaching a treatment decision. FUNDING: No external funding.
引用
- Sabatine MS, Bergmark BA, Murphy SA, et al. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. Lancet. 2021. PMID: 34793745. doi:10.1016/S0140-6736(21)02334-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。